NDANASALSPRAY, METERED
Approved
Nov 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
ASTELIN (azelastine hydrochloride) by Gen Pharmaceuticals is clinical pharmacology azelastine hydrochloride, a phthalazinone derivative, exhibits histamine h 1 -receptor antagonist activity in isolated tissues, animal models, and humans. Approved for allergic rhinitis, seasonal allergic rhinitis. First approved in 1996.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H 1 -receptor antagonist activity in isolated tissues, animal models, and humans. Astelin Nasal Spray is administered as a racemic mixture with no difference in pharmacologic activity noted between the…
Worked on ASTELIN at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.